A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies
Phase of Trial: Phase II
Latest Information Update: 16 May 2019
Price : $35 *
At a glance
- Drugs Narsoplimab (Primary)
- Indications Thrombotic microangiopathy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Omeros Corporation
- 09 Jan 2019 Planned End Date changed from 1 Jun 2018 to 1 Oct 2019.
- 09 Jan 2019 Planned primary completion date changed from 1 Jun 2018 to 1 Oct 2019.
- 17 Jun 2018 Results from analysis (N=19, 18 from the study and 1 from compassionate use), presented at the 23rd Congress of the European Haematology Association.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History